Fund moves
6.2%Stake · was 6.2%
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
KZIA · NASDAQ · Pharmaceutical Preparations · Foreign private issuer
Kazia Therapeutics (KZIA) · oqro.io/stocks/KZIA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$4.92−0.45 (−8.38%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Kazia Therapeutics was filed in the last 90 days. The latest on record was on Jul 29, 2008.
Since 2006, Kazia Therapeutics insiders reported 89 open-market purchases and 13 sales on Forms 4 and 5, with purchases in 3 different years, most recently 2008.
No open-market sale by an insider of Kazia Therapeutics (KZIA) was filed with the SEC in the last 90 days.
No trade in Kazia Therapeutics (KZIA) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−34.2% (−$2.56) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $7.48 on Nov 20, 2025 to $4.92 on Nov 20, 2026 (−34.2%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Sydney Nsw. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Last 12 months
−34.2%
Market value
–
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 1.45M shares sold short, +10.5% vs the previous count, 7.9 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Latest annual report filed Nov 17, 2026, compared with the one filed Nov 7, 2025. Read the filing
Source: SEC EDGAR, Form 20-F filed Nov 17, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Insiders of Kazia Therapeutics reported 89 open-market purchases and 13 sales since 2006; purchases in 3 different years, most recently 2008.
| Year | Bought | Sold |
|---|---|---|
| 2013 | — | $1.51M13×13 trades |
| 2008 | $5.29M2×2 trades | — |
| 2007 | $7.61M45×45 trades | — |
| 2006 | $1.52M42×42 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Fiscal year Jul 1, 2025 to Jun 30, 2026, from the annual report filed Nov 17, 2026. Figures are in AUD, the currency of the filing. Read the filing
+138% on the year before (42K AUD)
0 AUD the year before
0 AUD the year before
−81% on the year before (42K AUD)
Every annual report has a section where the company's managers explain the year's results (Item 5, Operating and financial review). In this report it runs to about 5,000 words.
We prepare our consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). As such, we are required to make certain estimates, judgments, and assumptions that management believes are reasonable based upon the information available. These estimates, judgments and assumptions affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. The critical accounting policies are summarised in Item 18. “Financial Statements-Note 3 - Critical accounting judgements, estimates and assumptions”.
Source: SEC EDGAR, Form 20-F filed Nov 17, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 47.4% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (21.4% on ATS, 26.0% with other brokers), above its 26-week average of 44.4%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: IBKR ATS (18.4%), UBS ATS (14.6%), SIGMA X2 (6.6%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Against the S&P 500 over the year
Since Nov 18, 2025, KZIA is down 14.6% and the index fund is up 4.5%: 19 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much KZIA moves
Beta 2.6 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).